As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Sarcopenia – pipeline landscape globally. Sarcopenia Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not active tend to lose muscle mass and strength. This can be due to a sedentary lifestyle, bed rest, or prolonged immobilization.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31257
Report Highlights
Global Insight Service’s, Sarcopenia – Drug Pipeline Landscape, 2023 report provides an overview of the Sarcopenia pipeline drugs. This report covers detailed insights on Sarcopenia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Sarcopenia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Key Players
- AAVogen Inc
- Anagenesis Biotechnologies SAS
- ARMGO Pharma Inc
- Bioleaders Corp
- Biophytis
- Dystrogen Therapeutics SA
- Elixir Pharma Co Ltd
- Encell Co Ltd
- Gerologix Inc
- ImmunoForge Inc.
- Keren Therapeutics
- Klotho Therapeutics Inc
- MedAvail Holdings Inc
Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31257
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700